The impact of the Orphan Drug Act on drug discovery

Expert Opinion on Drug Discovery

Volumn 1, Issue 6, 2006, Pages 521-524

  Haffner, Marlene E ^a   Maher, Paul D ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 41049098130     PISSN: 17460441     EISSN: 1746045X     Source Type: Journal    
DOI: 10.1517/17460441.1.6.521     Document Type: Review

References (22)

1. CAVALIER GM: Pushing parentless pharmaceuticals: toward an international home for orphan drugs and a cure for zebra diseases. Law Policy Int. Bus. (1996) 27:447-476.
2. RADOS C: Orphan products: hope for people with rare diseases. FDA Consumer Magazine. Nov-Dec (2003).
3. FUTERMAN AH, SUSSMAN JL, HOROWITZ M, SILMAN I, ZINIRAN A: New directions in the treatment of Gaucher disease. Trends Pharmacol. Sci. (2004) 25(3):147-151.
4. HERSHFIELD MS, BUCKLEY RH, GREENBERG ML et al.: Treatement of adenosine demainase deficincy with polyethylene glycol modified adenosine deaminase. N. Engl. J. Med. (1987) 316:589-596.
5. MAEDER T: The Orphan Drug backlash. Sci. Am. (2003) 288(5):80.
6. WAX PM: Elixirs, diluents and the passage of the 1938 federal food, drug and cosmetic act. Ann. Intern. Med. (1995) 122(6):456-461.
7. SCOTT CR: The genetic tyrosinemias. Am. J. Med. Genet. Part C Semin. Med. Genet. (2006) 142C:121-126.
8. VERWEIJ J, JUDSON I, VAN OOSTEROM A: STI571: a magic bullet? Eur. J. Cancer. (2001) 37(15):1816-1819.
9. CHAFFEE S, HERSFIELD MS: Imuune response to polyethylene glycol modified bovine adenosine deaminase (PEG-ADA). Pediatr Res. (1990) 27(4 Pt 2):155A.
10. MEDINA J, GARCIA BL, MORENO MJ, TRAPERO MM, MORENO OR: Therapeutic advantages of pegylation of IFN-á in chronic hepatitis C. Rev. Esp. Enferm. Dig. (2003) 95(8):568-574, 561-567.
11. STROM S: A Small Charity takes the Reins in Fighting a Neglected Diesease, New York Times, July 31 (2006).
12. BIDOU L, HATIN I, PEREZ N, ALLAMAND V, PANTHIER JJ, ROUSSET JP: Premature stop codons involved in muscular dystrophies show a broad spectrum of read through efficiencies in response to gentamicin treatment. Gene Ther. (2004) 11:619-267.
13. SCONE EA, KHAN TI, WYNNE HA et al.: The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regime. Blood (2005) 106:2329-2333.
14. http://www.fda.gov/orphan/grants/previous. htm OOPD. Grant no. FDR-000285-01 to ABUCHOWSKI A. Severe combined immunogenicity disease: enzyme therapy. Rockville (MD).
15. http://www.fda.gov/orphan/designat/list.htm Orphan Designations 1999-1255 and 2006-2212.
16. http://www.fda.gov/orphan/odreg.htm Ammendment to Orphan Drug Act Pub. L. No. 100-290 (1988).
17. http://www.rarediseases.org/news/speeches/news/speeches/ wiley-lecture-0405 MEYERS A: Wiley Lecture Delivered by Abbey Meyers, at the annual meeting of the FDA Alumni Association in Washington, DC, April 6 (2005).
18. http://www.fda.gov/Cber/gdlns/orphan.htm The Orphan Drug Regulations. CFR 21 Part 316. Docket No. 85N-0483.
19. http://money.cnn.com/2005/07/08/news/midcaps/orphan/index.htm SMITH A: From orphan to blockbuster? Biotechs lead the way in getting orphan drugs to market, and sometimes they actually make money. CNN Money.
20. http://www.fda.gov/oc/history/historyoffda/section2.html SWANN JP: History of the FDA: The Federal Food Drug and Cosmetic Act of 1938. FDA History Office.
21. http://www.communities.ninemsn.com/tyrosinemia/ntbc.msnw NEERGAARD L: FDA OKs drug to fight liver disease. Associated Press (23 Jan 2002).
22. http://www.oneworldhealth.org/business/index.php Institute for One World Health.